Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 plus abiraterone/prednisone versus placebo plus abiraterone/prednisone in chemotherapy-naive bone-predominant metastatic castration-resistant prostate cancer
NL-OMON54688Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of radium-223 dichloride, abiraterone, prednisone and prednisolone in castration-resistant prostate cancer (CRPC), sponsored by Bayer. Primary endpoint: Symptomatic skeletal event-free survival. Started Nov 2015; status: active, not recruiting.
02
Drugs
radium-223 dichlorideabirateroneprednisoneprednisolone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON54688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54688.